Novak E, Paxton L M, Bye A, Patel R, Zurenko G E, Francom S F
Upjohn Company, Kalamazoo, Michigan 49001-9988.
Antimicrob Agents Chemother. 1990 Dec;34(12):2342-7. doi: 10.1128/AAC.34.12.2342.
In this study, local and systemic tolerance and pharmacokinetics of trospectomycin sulfate in human beings were evaluated for the first time. Trospectomycin sulfate (U-63,366F; trospectomycin) or sterile saline was administered to 96 healthy male volunteers in doses ranging from 0.25 ml (75 mg) to 3.3 ml (1,000 mg) in a single intramuscular injection in a double-blind, randomized design. Volunteers were screened to establish baseline vital signs and laboratory test values. Pain and tenderness at the injection site, which occurred at doses of 450 mg and above, were the most common side effects; they were mild in severity and transient. Adverse drug experiences reported by subjects included nausea, dizziness, light-headedness, diaphoresis, costal pain, and perioral numbness. The perioral numbness (paresthesia) experienced at doses of 750, 900, and 1,000 mg was probably drug related. No Clostridium difficile toxin was detected in fecal samples. Pharmacokinetic calculations based on data obtained by high-performance liquid chromatography showed that after a 1,000-mg intramuscular dose of trospectomycin (3.3 ml), the serum mean half-life was 1.85 h (1.70 to 2.02 h), mean area under the serum concentration-time curve was 140.2 micrograms.h/ml and was linear with dose, mean peak concentration was 28.3 micrograms/ml (20.4 to 34.7 micrograms/ml), mean time to maximum concentration was 71 min (30 to 120 min), and the elimination rate constant was 0.307 h-1. The elimination rate constant and half-life did not vary with dose. Little trospectomycin was detected in 2-day fecal collections. A few randomly occurring abnormal clinical laboratory test values and vital signs were observed. For the trospectomycin-treated group, creatinine phosphokinase increased substantially for 24 h after injection and then decrease through day 5, while serum glutamic oxalacetic transaminase and lactate dehydrogenase increased slightly.
在本研究中,首次评估了硫酸壮观霉素在人体中的局部和全身耐受性以及药代动力学。以双盲、随机设计,将硫酸壮观霉素(U-63,366F;壮观霉素)或无菌生理盐水以0.25毫升(75毫克)至3.3毫升(1000毫克)的剂量单次肌内注射给予96名健康男性志愿者。对志愿者进行筛查以建立基线生命体征和实验室检查值。注射部位疼痛和压痛出现在450毫克及以上剂量时,是最常见的副作用;其严重程度较轻且为一过性。受试者报告的药物不良反应包括恶心、头晕、头昏、出汗、肋痛和口周麻木。在750、900和1000毫克剂量时出现的口周麻木(感觉异常)可能与药物有关。粪便样本中未检测到艰难梭菌毒素。基于高效液相色谱获得的数据进行的药代动力学计算表明,肌内注射1000毫克壮观霉素(3.3毫升)后,血清平均半衰期为1.85小时(1.70至2.02小时),血清浓度-时间曲线下平均面积为140.2微克·小时/毫升且与剂量呈线性关系,平均峰值浓度为28.3微克/毫升(20.4至34.7微克/毫升),平均达峰时间为71分钟(30至120分钟),消除速率常数为0.307小时-1。消除速率常数和半衰期不随剂量变化。在2天的粪便收集物中检测到少量壮观霉素。观察到一些随机出现的异常临床实验室检查值和生命体征。对于壮观霉素治疗组,注射后24小时内肌酸磷酸激酶大幅升高,然后在第5天下降,而血清谷草转氨酶和乳酸脱氢酶略有升高。